Viloxazine Dosage

Medically reviewed by Drugs.com. Last updated on Jun 18, 2025.

Usual Pediatric Dose for Attention Deficit Disorder

6 to 11 years:
Initial dose: 100 mg orally once a day

• May titrate in increments of 100 mg per week based on response and tolerability

Maximum dose: 400 mg/day

12 to 17 years:
Initial dose: 200 mg orally once a day

• After 1 week, may titrate to 400 mg once a day based on response and tolerability

Maximum dose: 400 mg/day

Comments:

• Assess heart rate and blood pressure prior to initiating treatment.
• Screen patients for a personal or family history of suicide, bipolar disorder, and depression prior to initiating treatment.
• Pharmacologic treatment for Attention-Deficit Hyperactivity Disorder (ADHD) may be needed for extended periods; periodically reevaluate and adjust dosage as needed.

Use: For the treatment of ADHD in pediatric patients 6 years or older.

Renal Dose Adjustments

Mild to moderate (estimated glomerular filtration rate [eGFR] 30 to 89 mL/min/1.73 m2): No adjustment recommended

Severe renal impairment (eGFR less than 30 mL/min/1.73 m2):

• Initial dose: 100 mg orally once a day
• May titrate in increments of 50 to 100 mg weekly based on response and tolerability
• Maximum dose: 200 mg/day

Liver Dose Adjustments

Not recommended

Precautions

US BOXED WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

• In clinical studies, higher rates of suicidal thoughts and behavior were reported in pediatric patients with ADHD receiving this drug than in patients treated with placebo.
• Closely monitor patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS:

• Concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis
• Concomitant use of sensitive CYP450 1A2 substrates or CYP450 1A2 substrates with a narrow therapeutic range

Safety and efficacy have not been established in patients younger than 6 years or older than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Take orally once a day with or without food; do not cut, crush, or chew the capsules
• May open capsule and sprinkle contents over a teaspoon of applesauce; consume in its entirety within 2 hours without chewing

Storage requirements:

• If mixed with applesauce, use within 2 hours; do not store for future use

Monitoring:

• Assess heart rate and blood pressure prior to therapy, following any dose increase, and periodically during therapy
• Screen for personal or family history of suicide, bipolar disorder, and depression prior to therapy
• Monitor weight
• Monitor for clinical worsening and emergence of suicidal thoughts and behaviors, especially during therapy initiation and with dose changes

Patient advice:

• Patients/caregivers should be instructed to read the US FDA-approved patient labeling (Medication Guide).
• Family members and caregivers should be informed of the possibility of suicidal thoughts and behaviors and instructed to report behavioral changes or emergence of suicidal thoughts and behaviors promptly.
• Patients/caregivers should understand that there is a potential for somnolence and fatigue; they should understand how this drug affects them prior to engaging in activities requiring mental alertness.

Frequently asked questions

• Qelbree vs. Strattera: How do they compare?

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer